Could a simple supplement tame immunotherapy side effects in head and neck cancer?
NCT ID NCT07485296
First seen Mar 23, 2026 · Last updated Jun 13, 2026 · Updated 13 times
Summary
This study is for people with advanced head and neck cancer who are starting a standard immunotherapy drug called pembrolizumab. Researchers want to see if adding a special supplement called a postbiotic can reduce side effects and improve how the body responds to treatment. About 45 participants will receive either the postbiotic or a placebo for 4 cycles, and their gut and mouth bacteria will be monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Clinico Humanitas
RECRUITINGRozzano, Milano, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.